Andrographolide for COVID-19: real-time meta-analysis of 7 studies (Version 8)

Significantly lower risk is seen for recovery. 2 studies from 2 independent teams in 2 countries show significant benefit.

Meta-analysis using the most serious outcome reported shows 27% [-8‑50%] lower risk, without reaching statistical significance. Results are similar for Randomized Controlled Trials. Early treatment is more effective than late treatment.

Control AndrographolideAndrograph..

1 RCT with 3,060 patients has not reported results (3 years late)1.

No treatment is 100% effective. Protocols combine safe and effective options with individual risk/benefit analysis and monitoring. Other treatments are more effective. A lipid-optimized formulation may be required for therapeutic concentrations of andrographolide. All data and sources to reproduce this analysis are in the appendix.